Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab
, , , und | 25. Apr. 2014
Über diesen Artikel
Online veröffentlicht: 25. Apr. 2014
Seitenbereich: 184 - 188
Eingereicht: 27. Aug. 2013
Akzeptiert: 18. Nov. 2013
DOI: https://doi.org/10.2478/raon-2013-0083
Schlüsselwörter
© by Robert Königsberg
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Robert Königsberg
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) – LB Cluster Translational Oncology, 3rd Medical Department – Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria / Applied Cancer Research – Institution for Translational Research Vienna (ACR –ITR VIEnna), Vienna, Austria
Julia Maierhofer
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria
Tanja Steininger
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria/ Applied Cancer Research – Institution for Translational Research Vienna (ACR –ITR VIEnna), Vienna, Austria
Gabriele Kienzer
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria / Institute for Radiodiagnostics, Kaiser Franz Josef-Spital, Vienna, Austria
Christian Dittrich
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria / Applied Cancer Research – Institution for Translational Research Vienna (ACR –ITR VIEnna), Vienna, Austria